AU2013315631B2 - HIV-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies - Google Patents

HIV-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies Download PDF

Info

Publication number
AU2013315631B2
AU2013315631B2 AU2013315631A AU2013315631A AU2013315631B2 AU 2013315631 B2 AU2013315631 B2 AU 2013315631B2 AU 2013315631 A AU2013315631 A AU 2013315631A AU 2013315631 A AU2013315631 A AU 2013315631A AU 2013315631 B2 AU2013315631 B2 AU 2013315631B2
Authority
AU
Australia
Prior art keywords
pct
rule
substitute sheet
scaffold
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013315631A
Other languages
English (en)
Other versions
AU2013315631A1 (en
Inventor
Phillip W. Berman
Kathryn MESA
Javier Morales
Gwen Tatsuno
Bin Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2013315631A1 publication Critical patent/AU2013315631A1/en
Application granted granted Critical
Publication of AU2013315631B2 publication Critical patent/AU2013315631B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2013315631A 2012-09-11 2013-09-11 HIV-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies Ceased AU2013315631B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699680P 2012-09-11 2012-09-11
US61/699,680 2012-09-11
PCT/US2013/059243 WO2014043220A2 (en) 2012-09-11 2013-09-11 Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies

Publications (2)

Publication Number Publication Date
AU2013315631A1 AU2013315631A1 (en) 2015-04-30
AU2013315631B2 true AU2013315631B2 (en) 2018-04-19

Family

ID=50278843

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013315631A Ceased AU2013315631B2 (en) 2012-09-11 2013-09-11 HIV-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies

Country Status (7)

Country Link
US (2) US9731002B2 (enExample)
EP (1) EP2928492A4 (enExample)
CN (1) CN106170296A (enExample)
AU (1) AU2013315631B2 (enExample)
CA (1) CA2929937C (enExample)
IN (1) IN2015DN03026A (enExample)
WO (1) WO2014043220A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012279018B2 (en) 2011-07-05 2017-06-08 Children's Medical Center Corporation N-terminal deleted GP120 immunogens
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
US10517942B2 (en) 2015-08-01 2019-12-31 The Regents Of The University Of California Polypeptide glycopeptide fragments from the V1/V2 and V3 domains of the HIV-1 envelope protein gp 120
CN106800603B (zh) * 2017-01-24 2020-07-28 中国食品药品检定研究院 检测抗hiv抗体的adcc活性的方法
US20200231633A1 (en) * 2017-07-19 2020-07-23 The Regents Of The University Of California MGAT1-Deficient Cells for Production of Vaccines and Biopharmaceutical Products
WO2020081328A1 (en) * 2018-10-15 2020-04-23 The Regents Of The University Of California Complement component 1s (c1s) deficient cells for production of vaccines and biopharmaceutical proteins
EP3890776A4 (en) * 2018-12-03 2022-12-28 International AIDS Vaccine Initiative RECOMBINANT HIV ENV POLYPEPTIDES AND THEIR USES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097822A1 (en) * 2004-04-09 2005-10-20 University Of Manitoba Identification of the precise amino acid sequence of the epitope recognized by the potent neutralizing human anti-hiv-1 monoclonal antibody igg1b12
WO2012003234A2 (en) * 2010-06-30 2012-01-05 Torrey Pines Institute For Molecular Studies Env trimer immunogens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6268199A (en) * 1998-09-29 2000-04-17 University Of Kansas Medical Center Live virus vaccines to protect primates from hiv-1 infection and disease
US9782472B2 (en) 2008-10-04 2017-10-10 The Regents Of The University Of California Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
CN102803292A (zh) * 2009-04-20 2012-11-28 辉瑞公司 蛋白质糖基化的控制及其相关组合物和方法
WO2011008863A2 (en) * 2009-07-14 2011-01-20 Lucia Irene Gonzalez Stereoisomer peptides and their polymer conjugates for hiv disease
CA2858347C (en) 2011-12-05 2020-07-07 New York University V1v2 immunogens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097822A1 (en) * 2004-04-09 2005-10-20 University Of Manitoba Identification of the precise amino acid sequence of the epitope recognized by the potent neutralizing human anti-hiv-1 monoclonal antibody igg1b12
WO2012003234A2 (en) * 2010-06-30 2012-01-05 Torrey Pines Institute For Molecular Studies Env trimer immunogens

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOORES K.J. et al., "Variable Loop Glycan Dependency of the Broad and Potent HIV-1-Neutralizing Antibodies PG9 and PG16", Journal of Virology, Oct. 2010, pages 10510-10521 *
PINTER A. et al., "Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120", Vaccine, 1998, Vol 16, No. 19, pages 1803-11 *
YU, B. et al., "Glycoform and Net Charge Heterogeneity in gp120 Immunogens Used in HIV Vaccine Trials", PLOS ONE, August 2012, Vol. 7, Issue 8, e43903 *

Also Published As

Publication number Publication date
EP2928492A4 (en) 2017-09-13
WO2014043220A2 (en) 2014-03-20
EP2928492A2 (en) 2015-10-14
AU2013315631A1 (en) 2015-04-30
US20150246111A1 (en) 2015-09-03
US10507239B2 (en) 2019-12-17
CA2929937A1 (en) 2014-03-20
CN106170296A (zh) 2016-11-30
US9731002B2 (en) 2017-08-15
CA2929937C (en) 2020-01-07
US20180036401A1 (en) 2018-02-08
WO2014043220A3 (en) 2016-10-27
IN2015DN03026A (enExample) 2015-10-02

Similar Documents

Publication Publication Date Title
US10507239B2 (en) V1/V2 fragments of a HIV-1 envelope glycoprotein
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
US20230190910A1 (en) Scaffolded hiv-1 vaccine immunogens
US10058604B2 (en) Soluble HIV-1 envelope glycoprotein trimers
WO2013039792A1 (en) Immunogens based on an hiv-1 gp120 v1v2 epitope
EA034639B1 (ru) Вакцины против вируса гриппа и их применения
AU2020367242B2 (en) Influenza virus vaccines and uses thereof
JP2015521592A (ja) 安定化されたｇｐ１２０
KR102643280B1 (ko) 변형된 인자 h 결합 단백질
Saha et al. Designed cyclic permutants of HIV-1 gp120: implications for envelope trimer structure and immunogen design
CN112313245A (zh) 屋尘螨变应反应的治疗和预防
KR20180038557A (ko) 타겟 폴리펩티드를 제시하기 위한 폴리펩티드 캐리어 및 이의 용도
Du et al. Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein
Gao et al. Centralized HIV-1 envelope immunogens and neutralizing antibodies
US10517942B2 (en) Polypeptide glycopeptide fragments from the V1/V2 and V3 domains of the HIV-1 envelope protein gp 120
CA3117390A1 (en) Recombinant gp120 protein with v1-loop deletion
JP7167088B2 (ja) インフルエンザウイルスワクチンおよびその使用
WO2020117740A1 (en) Recombinant hiv env polypeptides and their uses
CA2509387A1 (en) Peptide oligomers for use as hiv vaccines
WO2009021230A1 (en) Hiv-1 gp41 neutralization domain and use thereof
Morales V1/V2 domain scaffolds to improve the magnitude and quality of protective antibody responses to HIV-1
EP3104884B1 (en) A new non-hiv vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against hiv infection
HK40036020A (zh) 屋尘螨变应反应的治疗和预防

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired